Targeted therapeutic options in the treatment of Breast Cancer

Abstract

The recent application of targeted therapies such as biologics, biosimilars, and other targeted biological agents in the treatment of diverse subtypes of breast cancer has been facilitated by the decoding of the human genome and the subdivision of breast cancer on a molecular level. This review focuses on targeted therapeutic approaches used in breast cancer therapy, such as anti-HER2 targeted monoclonal antibodies, CDK4/6 inhibitors, immune checkpoint inhibitors, blockers of the PI3K/AKT/mTOR signaling pathways, PARP inhibitors, Antibody-Drug Conjugates (ADCs), and anti-VEGF agents. Moreover, this paper specifically discusses the role of trastuzumab in the treatment of HER2-positive breast tumors, as well as its approved biosimilars which aim to make breast cancer treatment affordable, while preventing cancer recurrence and improving overall therapeutic efficacy